SGTX — Sigilon Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $56.50m
- $17.21m
- $12.94m
- 30
- 21
- 77
- 38
Annual cashflow statement for Sigilon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.8 | -43.9 | -54.6 | -77.3 | -43.6 |
| Depreciation | |||||
| Non-Cash Items | 0.939 | 4.07 | 7.57 | 11.2 | 10.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 59.8 | -10.9 | -15.5 | -13.4 | -19.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 38.3 | -50.1 | -61.6 | -78.4 | -51.5 |
| Capital Expenditures | -1.65 | -1.21 | -0.972 | -1.83 | -0.537 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | -16.2 | -11.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.65 | -1.21 | -0.972 | -18.1 | -12.1 |
| Financing Cash Flow Items | -0.058 | -0.078 | -0.226 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24.2 | 63.2 | 189 | 1.55 | -1.61 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 60.9 | 12 | 127 | -94.9 | -65.2 |